Filter By Category
Archives
Share on -
AROXYBUTYNIN
Generic Name: AROXYBUTYNIN
ABSTRACT -
Aroxybutynin is the R-enantiomer of oxybutynin and acts as a muscarinic receptor antagonist. Its principal late-stage development has been as a component of AD109, a fixed-dose oral combination with atomoxetine intended to improve upper-airway muscle activity in obstructive sleep apnoea. It is not a broadly approved standalone treatment for sleep apnoea.
DOSAGE –
-
-
No approved aroxybutynin monotherapy dosage is established for obstructive sleep apnoea. Phase 3 AD109 studies used a once-at-bedtime tablet containing aroxybutynin 2.5 mg with atomoxetine 75 mg. This combination-study dose is not a recommendation for self-treatment and must not be recreated using separate products.
-
SIDE EFFECTS –
- Dry mouth
- Insomnia or disturbed sleep
- Nausea
- Constipation
- Urinary hesitancy or retention
- Blurred vision, palpitations, or increased heart rate
ALLRGIC REACTIONS–
(These symptoms may indicate a serious allergic or infusion reaction and require medical attention.)
- Rash or hives
- Facial, lip, tongue, or throat swelling
- Breathing difficulty
- Severe blistering or mucosal reaction
DRUG INTERACTIONS -
- Other anticholinergic medicines may increase dry mouth, constipation, blurred vision, and urinary retention
- The atomoxetine component introduces additional cardiovascular and metabolic interactions
- Alcohol or sedatives can worsen impairment and sleep-related risk
- Strong CYP2D6 inhibitors may affect atomoxetine exposure in the combination
PRECAUTIONS –
- Assess glaucoma, urinary retention, gastrointestinal obstruction, and cardiac history
- Monitor pulse and blood pressure when used with atomoxetine
- Use caution in older adults and patients sensitive to anticholinergic effects
- Pregnancy and breastfeeding use requires product-specific medical advice
WARNINGS –
- Do not assemble the investigational fixed dose from separate oxybutynin and atomoxetine products
- Acute urinary retention, severe eye pain, or marked tachycardia requires urgent care
- The safety and approval status of AD109 must be checked in the relevant country
Share on -
. Developed by